Doyle John Brendan 4
4 · COGNITION THERAPEUTICS INC · Filed Feb 5, 2026
Research Summary
AI-generated summary of this filing
Cognition Therapeutics (CGTX) CFO John Doyle Receives 200,000 RSUs
What Happened John Brendan Doyle, Chief Financial Officer of Cognition Therapeutics (CGTX), received an award of 200,000 restricted stock units (RSUs) on 2026-02-03 (acquisition code A). On 2026-02-04 the company withheld 26,921 shares to satisfy tax withholding obligations related to the RSU vesting; those shares were recorded as disposed at $1.03 each for a total withholding value of $27,729. The RSUs are contingent rights to receive common shares upon settlement and are not an open-market purchase.
Key Details
- Grant: 200,000 RSUs granted on 2026-02-03 (acquisition at $0.00 per share).
- Withholding: 26,921 shares withheld on 2026-02-04 at $1.03 each = $27,729 (tax withholding, disposition code F).
- Footnotes: F1 — each award is an RSU representing a contingent right to one share on settlement; F2 — withheld shares were to cover tax withholding on RSU vesting.
- Form 4 filed: 2026-02-05. No late-filing flag provided in the supplied details.
- Shares owned after the transactions: not specified in the provided filing summary.
Context RSU grants are non-cash compensation that convert to actual shares only upon settlement/vesting. Share withholding to cover taxes is a routine administrative step (a form of cashless settlement) and reflects tax obligations rather than an open-market sale signaling sentiment.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-03+200,000→ 645,990 total - Tax Payment
Common Stock
[F2]2026-02-04$1.03/sh−26,921$27,729→ 619,069 total
Footnotes (2)
- [F1]Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
- [F2]Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.